by Portfolio Grader | April 24, 2013 9:00 am
This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health’s (NASDAQ:GHDX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock currently has a trailing PE Ratio of 117.90. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.
Acorda Therapeutics’ (NASDAQ:ACOR) rating weakens this week, dropping to a D versus last week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Amarin (NASDAQ:AMRN) earns a D this week, falling from last week’s grade of C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of April 24, 2013, 18% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.
Exelixis (NASDAQ:EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of April 24, 2013, 20.4% of outstanding Exelixis shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.
This week, Trius Therapeutics’ (NASDAQ:TSRX) rating worsens to a D from the company’s C rating a week ago. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. The stock price has fallen 6.6% over the past month, worse than the 1.1% increase the Nasdaq has seen over the same period of time. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
This week, Discovery Laboratories (NASDAQ:DSCO) drops from a C to a D rating. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. Share prices fell 25% over the past month. For a full analysis of DSCO stock, visit Portfolio Grader.
Slipping from a C to a D rating, Achillion (NASDAQ:ACHN) takes a hit this week. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. Wall Street appears to agree with the stock downgrade, with share prices dropping 14.5% over the past month. As of April 24, 2013, 12.8% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: https://investorplace.com/2013/04/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-3/
Short URL: http://invstplc.com/1foPQ3a
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.